The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon ... Read more
Advances in screening technologies have enabled the identification of interactive gene combinations, enabling the development of lead candidates that leverage the principle of synthetic lethality for cancer treatment
To order this 485+ page report, which features 195+ figures and 200+ tables, please visit this
Advances in screening technologies have enabled the identification of interactive gene combinations, enabling the development of lead candidates that leverage the principle of synthetic lethality for cancer treatment
To order this 485+ page report, which features 195+ figures and 200+ tables, please visit this ... Read more
Advances in molecular screening technology have enabled the identification of novel synthetic lethal gene combinations, enabling the development of lead candidates that leverage the aforementioned phenomenon to offer therapeutic benefit.
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
To order this 330+ page report, please visit this link
Key Inclusions
A detailed assessment of the current market landscape of targeted protein degradation-based therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters),
The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are ... Read more
STING, having generated significant interest within the medical research community, is currently considered one of the fastest growing areas of cancer immunotherapy and is being pursued by several large pharmaceutical companies
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
To order this 330+ page report, please visit this link
Key Inclusions
A detailed assessment of the current market landscape of targeted protein degradation-based therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, company size and location of
Despite the fact that biopharmaceuticals offer significant profit margins, innovator companies are plagued by high costs of development, complex production protocols and special procedures and equipment for fill / finish operations. Consequently, a number of drug manufacturers have demonstrated a preference for outsourcing fill / finish operations of such products.
To order this 480+ page report, which features 350+ figures and 260+ tables, please visit
Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought about a paradigm shift in at-home healthcare, enabling users to administer (life-saving) medications without having to rely on medical professionals
Roots Analysis is pleased to announce the publication of its recent study, titled “ ... Read more
To order this detailed 480+ page report, please visit this link
Key Inclusions
A detailed assessment of the current market landscape, including information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates,
In recent years, the concept of STING pathway targeting therapeutics has generated a lot of enthusiasm within the medical science community. The growing popularity of this therapeutic technique has not only garnered the interest of several medical researchers (reflected in the increasing volume of scientific literature (1,000+ articles published since 2015) on this subject), but also industry stakeholders focused on drug development (evident in the growing number of clinical ... Read more
A steadily growing demand for biologic fill / finish services has generated a range of new opportunities for contract service providers; stakeholders have invested heavily to ensure product integrity and safety
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
To order this detailed 310+ page report, please visit this link
Key Inclusions
A detailed assessment of the current market landscape of therapeutics targeting STING pathway, based on several parameters, such as type of STING modulator (agonist or antagonist),
Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.
To order this 530+ page report, which features 160+ ... Read more
Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.
To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this link
Key Inclusions
A detailed review of the overall landscape of companies developing RNAi therapeutics, including information on phase of development (marketed, clinical, and
Proteome profiling is a technically complex and financially demanding field of research, as a result both pharmaceutical companies and research institutes prefer to rely on specialty service providers that claim to have the required expertise
